InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: None

Tuesday, 01/23/2018 8:28:20 AM

Tuesday, January 23, 2018 8:28:20 AM

Post# of 2809
Very interesting that a tiny company has 3-4 presentations in ASCO

The results are encouraging - it is a long term pure oncology play - already collaborations with BP
Question will be - who will buy them out early to avoid sharing the compounds with others

1. BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cellshttps://finance.yahoo.com/news/biolinerx-presents-preclinical-data-asco-130000549.html

2. BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studieshttps://finance.yahoo.com/news/biolinerx-reports-data-asco-sitc-120000054.html

3. BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancerhttps://finance.yahoo.com/news/biolinerx-announces-partial-monotherapy-results-120000366.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLRX News